These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31958164)

  • 21. Rheumatoid arthritis seems to have DMARD treatment decision influenced by fibromyalgia.
    Chakr RM; Brenol C; Ranzolin A; Bernardes A; Dalosto AP; Ferrari G; Scalco S; Olszewski V; Kohem C; Monticielo O; Brenol JC; Xavier RM
    Rev Bras Reumatol; 2016 Dec; ():. PubMed ID: 28040332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treat-to-target strategies aiming at additional ultrasound remission is associated with better control of disease activity and less flare in rheumatoid arthritis.
    Geng Y; Wang L; Zhang X; Ji L; Deng X; Zhang Z
    Clin Rheumatol; 2021 Jan; 40(1):113-121. PubMed ID: 32514681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pain Mechanisms Associated With Disease Activity in Patients With Rheumatoid Arthritis Treated With Disease-Modifying Antirheumatic Drugs: A Regression Tree Analysis.
    Wohlfahrt A; Muhammad LN; Song J; Dunlop DD; Neogi T; Bingham CO; Bolster MB; Marder W; Clauw DJ; Lee YC
    J Rheumatol; 2023 Jun; 50(6):741-747. PubMed ID: 36642431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis.
    Ranzolin A; Brenol JC; Bredemeier M; Guarienti J; Rizzatti M; Feldman D; Xavier RM
    Arthritis Rheum; 2009 Jun; 61(6):794-800. PubMed ID: 19479706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of depression, anxiety, fatigue, and fibromyalgia on the evaluation of the remission status in patients with rheumatoid arthritis.
    Inanc N; Yilmaz-Oner S; Can M; Sokka T; Direskeneli H
    J Rheumatol; 2014 Sep; 41(9):1755-60. PubMed ID: 25086073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic Drugs.
    Dagliati A; Plant D; Nair N; Jani M; Amico B; Peek N; Morgan AW; Isaacs J; Wilson AG; Hyrich KL; Geifman N; Barton A;
    Arthritis Rheumatol; 2020 Oct; 72(10):1632-1642. PubMed ID: 32475078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression.
    Naredo E; Collado P; Cruz A; Palop MJ; Cabero F; Richi P; Carmona L; Crespo M
    Arthritis Rheum; 2007 Feb; 57(1):116-24. PubMed ID: 17266071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database.
    Ranganath VK; Paulus HE; Onofrei A; Khanna D; Reed G; Elashoff DA; Kremer JM; Furst DE
    J Rheumatol; 2008 Oct; 35(10):1966-71. PubMed ID: 18785317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ultrasound-detected joint inflammation and B cell count: related variables for rituximab-treated RA patients?
    Valor L; Martínez-Estupiñán L; Janta I; Nieto JC; Ovalles-Bonilla JG; González-Fernández C; Del Rio T; Hernández-Flórez D; Monteagudo I; López-Longo FJ; Naredo E
    Rheumatol Int; 2016 Jun; 36(6):793-7. PubMed ID: 27072348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
    Kim SC; Solomon DH; Liu J; Franklin JM; Glynn RJ; Schneeweiss S
    Am J Med; 2015 May; 128(5):539.e7-17. PubMed ID: 25534420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and evaluation of a novel ultrasound score for large joints in rheumatoid arthritis: one year of experience in daily clinical practice.
    Hartung W; Kellner H; Strunk J; Sattler H; Schmidt WA; Ehrenstein B; Fleck M; Backhaus M
    Arthritis Care Res (Hoboken); 2012 May; 64(5):675-82. PubMed ID: 22183834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of rheumatoid arthritis following adjunct statin therapy.
    Das S; Mohanty M; Padhan P
    Indian J Pharmacol; 2015; 47(6):605-9. PubMed ID: 26729950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.
    Wechalekar MD; Lester S; Proudman SM; Cleland LG; Whittle SL; Rischmueller M; Hill CL
    Arthritis Rheum; 2012 May; 64(5):1316-22. PubMed ID: 22135142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status.
    Hagen M; Englbrecht M; Haschka J; Reiser M; Kleyer A; Hueber A; Manger B; Figueiredo C; Cobra JF; Tony HP; Finzel S; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Lorenz HM; Nüsslein H; Alten R; Henes J; Krüger K; Schett G; Rech J
    J Rheumatol; 2019 May; 46(5):460-466. PubMed ID: 30504510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis.
    Mäkinen H; Kautiainen H; Hannonen P; Möttönen T; Leirisalo-Repo M; Laasonen L; Korpela M; Blåfield H; Hakola M; Sokka T
    J Rheumatol; 2007 Feb; 34(2):316-21. PubMed ID: 17183623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Register-based observational study of associations between inflammatory remission, formal treatment targets and the use of disease-modifying antirheumatic drugs among patients with early rheumatoid arthritis.
    Lindqvist J; Askling J; Lampa J
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 37973534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Musculoskeletal ultrasound for predicting remission in patients with rheumatoid arthritis: results from a 1-year prospective study.
    Sapundzhieva T; Karalilova R; Batalov A
    Rheumatol Int; 2018 Oct; 38(10):1891-1899. PubMed ID: 30121699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.